Journal of the Korean Academy of Child and Adolescent Psychiatry

대한소아청소년정신의학회 (Korean Academy of Child and Adolescent Psychiatry)
권호 표지
DOI QR코드

DOI QR Code

정상인에서 메칠페니데이트가 학습에 미치는 영향

Effect of Methylphenidate on Learning in Normal Population

  • 나경세 (순천향대학교 의과대학 부천병원 정신건강의학교실) ;
  • 이소영 (순천향대학교 의과대학 부천병원 정신건강의학교실)
  • Na, Kyoung-Sae (Department of Psychiatry, Soonchunhyang University College of Medicine, Bucheon Hospital) ;
  • Lee, So-Young Irene (Department of Psychiatry, Soonchunhyang University College of Medicine, Bucheon Hospital)
  • 투고 : 2012.04.05
  • 심사 : 2012.06.02
  • 발행 : 2012.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Methylphenidate is a widely used stimulant for treatment of attention-deficit hyperactivity disorder (ADHD). In addition to core symptoms of attention and behavioral symptoms, methylphenidate is even effective for executive functions. However, abuse and misuse of stimulants, including methylphenidate, for the purpose of cognitive enhancement is an issue of concern worldwide. Some prejudices and misunderstandings against methylphenidate are popular ; however, little attention has been given to the neuropsychiatric evidence of methylphenidate for enhancement of cognitive function among healthy populations. In this article, our aim was to conduct a review of previous studies investigating the effect of methylphenidate in healthy populations. Findings from several recent studies have demonstrated the effectiveness of methylphenidate for enhancement of cognitive function in healthy populations. The mechanisms of cognitive enhancement are thought to be associated with motivation and the reward circuit in the brain. However, when considering the risk to benefit, an official discussion of the use of methylphenidate among healthy members of the population would be premature. Instead, investigation of epidemiological studies of the prevalence of misuse of stimulants among healthy members of the population, particularly adolescents and college students, is needed. In addition, based on achievements reported in previous studies, investigation of the effect of an approach using non-pharmacological enhancing motivation, which will in turn result in increased cognitive function would be helpful.

키워드

참고문헌

  1. Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M. OROS methylphenidate for the treatment of adults with attentiondeficit/ hyperactivity disorder. Expert Rev Neurother 2009;9:1121-1131. https://doi.org/10.1586/ern.09.65
  2. Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 2009;23:194-205. https://doi.org/10.1177/0269881108089809
  3. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006;16:351-356. https://doi.org/10.1089/cap.2006.16.351
  4. Choi EM. ‛Smart drug?' Caution on abuse and misuse of ADHD mediaction. Money Today 2011 Nov 1. Available from http://news.mt.co.kr/mtview.php?no=2011110110544791407&type=1
  5. Welsh MC, Pennington BF. Assessing frontal lobe functioning in children: Views from developmental psychology. Dev Neuropsychol 1988;4:199-230. https://doi.org/10.1080/87565648809540405
  6. Smith EE, Jonides J. Storage and executive processes in the frontal lobes. Science 1999;283:1657-1661. https://doi.org/10.1126/science.283.5408.1657
  7. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997;121:65-94. https://doi.org/10.1037/0033-2909.121.1.65
  8. Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002;3:617-628. https://doi.org/10.1038/nrn896
  9. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry 2005;57: 1336-1346. https://doi.org/10.1016/j.biopsych.2005.02.006
  10. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009;302:1084-1091. https://doi.org/10.1001/jama.2009.1308
  11. Johansen EB, Killeen PR, Russell VA, Tripp G, Wickens JR, Tannock R, et al. Origins of altered reinforcement effects in ADHD. Behav Brain Funct 2009;5:7. https://doi.org/10.1186/1744-9081-5-7
  12. Kobel M, Bechtel N, Weber P, Specht K, Klarhöfer M, Scheffler K, et al. Effects of methylphenidate on working memory functioning in children with attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 2009;13:516-523. https://doi.org/10.1016/j.ejpn.2008.10.008
  13. Kemner C, Jonkman LM, Kenemans JL, Böcker KB, Verbaten MN, Van Engeland H. Sources of auditory selective attention and the effects of methylphenidate in children with attention-deficit/hyperactivity disorder. Biol Psychiatry 2004;55:776-778. https://doi.org/10.1016/j.biopsych.2003.12.007
  14. Lufi D, Parish-Plass J, Gai E. The effect of methylphenidate on the cognitive and personality functioning of ADHD children. Isr J Psychiatry Relat Sci 1997;34:200-209.
  15. Konrad K, Gunther T, Hanisch C, Herpertz-Dahlmann B. Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:191-198. https://doi.org/10.1097/00004583-200402000-00015
  16. Kuhle HJ, Kinkelbur J, Andes K, Heidorn FM, Zeyer S, Rautzenberg P, et al. Self-regulation of visual attention and facial expression of emotions in ADHD children. J Atten Disord 2007;10:350-358. https://doi.org/10.1177/1087054706289944
  17. Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 2006;30: 1225-1245. https://doi.org/10.1016/j.neubiorev.2006.10.002
  18. Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology (Berl) 1993;111:1-16. https://doi.org/10.1007/BF02257400
  19. Hink RF, Fenton WH Jr, Tinklenberg JR, Pfefferbaum A, Kopell BS. Vigilance and human attention under conditions of methylphenidate and secobarbital intoxication: an assessment using brain potentials. Psychophysiology 1978;15:116-125. https://doi.org/10.1111/j.1469-8986.1978.tb01346.x
  20. Coons HW, Peloquin LJ, Klorman R, Bauer LO, Ryan RM, Perlmutter RA, et al. Effect of methylphenidate on young adult's vigilance and event-related potentials. Electroencephalogr Clin Neurophysiol 1981;51:373-387. https://doi.org/10.1016/0013-4694(81)90101-2
  21. Aman MG, Vamos M, Werry JS. Effects of methylphenidate in normal adults with reference to drug action in hyperactivity. Aust N Z J Psychiatry 1984;18:86-88. https://doi.org/10.3109/00048678409161040
  22. Strauss J, Lewis JL, Klorman R, Peloquin LJ, Perlmutter RA, Salzman LF. Effects of methylphenidate on young adults' performance and event-related potentials in a vigilance and a paired-associates learning test. Psychophysiology 1984;21:609-621. https://doi.org/10.1111/j.1469-8986.1984.tb00247.x
  23. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 1997;131:196-206. https://doi.org/10.1007/s002130050284
  24. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000;20:RC65.
  25. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 2004;161:1173-1180. https://doi.org/10.1176/appi.ajp.161.7.1173
  26. Tomasi D, Volkow ND, Wang GJ, Wang R, Telang F, Caparelli EC, et al. Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls. Neuroimage 2011;54:3101-3110. https://doi.org/10.1016/j.neuroimage.2010.10.060
  27. Ozaki TJ. Frontal-to-parietal top-down causal streams along the dorsal attention network exclusively mediate voluntary orienting of attention. PLoS One 2011;6:e20079. https://doi.org/10.1371/journal.pone.0020079
  28. Tomasi D, Volkow ND. Aging and functional brain networks. Mol Psychiatry 2012;17:471, 549-558.
  29. Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009;10:410-422. https://doi.org/10.1038/nrn2648
  30. U.S. Food and Drug Administration. Psychiatric Adverse Events Associated with Drug Treatment of ADHD: Review of Postmarketing Safety Data. Maryland: U.S. Food and Drug Administration;2006.
  31. Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 2003;64 Suppl 11:14-18. https://doi.org/10.4088/JCP.v64n0105
  32. Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008;165:604-609. https://doi.org/10.1176/appi.ajp.2008.07091465
  33. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008;165:597-603. https://doi.org/10.1176/appi.ajp.2007.07091486
  34. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90. https://doi.org/10.1001/archpedi.160.1.82
  35. Friedman RA. The changing face of teenage drug abuse--the trend toward prescription drugs. N Engl J Med 2006;354:1448-1450. https://doi.org/10.1056/NEJMp068010
  36. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;100:96-106. https://doi.org/10.1111/j.1360-0443.2005.00944.x
  37. Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 2004;5:421-425. https://doi.org/10.1038/nrn1390
  38. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008;456:702-705. https://doi.org/10.1038/456702a
  39. Sannerud C, Feussner G. Is Ritalin an abused drug? Does it meet the criteria of a Schedule II substance? In: Greenhill LL, Osman BB, editors. Ritalin, theory and practice. 2nd ed. New Rochelle, NY: Mary Ann Liebert;2000. p.27-44.

피인용 문헌

  1. Simultaneous Determination of Methylphenidate, Amphetamine and their Metabolites in Urine using Direct Injection Liquid Chromatography-Tandem Mass Spectrometry vol.5, pp.4, 2014, https://doi.org/10.5478/MSL.2014.5.4.104
  2. Proper administration of psychostimulants vol.61, pp.8, 2018, https://doi.org/10.5124/jkma.2018.61.8.502
  3. Pharmacological treatment for attention deficit hyperactivity disorder in adults vol.64, pp.1, 2012, https://doi.org/10.5124/jkma.2021.64.1.49